Cover Image
市場調查報告書

ARQULE, INC - 產品平台分析

ArQule, Inc. - Product Pipeline Review - 2015

出版商 Global Markets Direct 商品編碼 214159
出版日期 內容資訊 英文 45 Pages
訂單完成後即時交付
價格
Back to Top
ARQULE, INC - 產品平台分析 ArQule, Inc. - Product Pipeline Review - 2015
出版日期: 2015年05月29日 內容資訊: 英文 45 Pages
簡介

ArQule, Inc.是臨床開發階段的生物企業,運用從所未見的嶄新手法來發現與開發治療各種類型癌症的新一代低分子治療藥。

本報告提供ArQule, Inc.的治療藥開發平台現狀及各開發階段比較分析,彙整藥物標的,作用機制,給藥途徑,各分子類型的治療藥評估,最新的企業新聞和發表,後期階段及中止的計劃等相關資訊。

ArQule, Inc.的基本資料

ArQule, Inc.概要

  • 主要資訊
  • 企業資料

ArQule, Inc.:R&D概要

  • 主要的治療範圍

ArQule, Inc.:開發平台評估

  • 各開發階段的開發中產品
  • 單劑產品

ArQule, Inc.:開發中產品概況

  • 最後階段的開發中產品
    • 第三階段的產品/聯合治療模式
  • 臨床實驗階段的開發中產品
    • 第二階段的產品/聯合治療模式
    • 第一階段的產品/聯合治療模式
  • 初期階段產品開發中產品
    • 藥物研發中的產品/聯合治療模式

ArQule, Inc.:藥物簡介

  • tivantinib
  • ARQ-087
  • ARQ-092
  • ARQ-621
  • ARQ-736
  • ARQ-761
  • Small Molecules To Inhibit Kinase For Oncology

ArQule, Inc.:開發平台分析

  • 標的別
  • 各給藥途徑
  • 各分子類型
  • 各作用機制

ArQule, Inc.:最近的開發平台趨勢

ArQule, Inc.:暫停中的計劃

ArQule, Inc.:開發中止的開發中產品

  • 開發中止的開發中產品簡介
    • ARQ-171
    • tivantinib

ArQule, Inc.:企業發表

ArQule, Inc.:總公司和子公司的所地

附錄

圖表

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC07103CDB

Summary

Global Markets Direct's, 'ArQule, Inc. - Product Pipeline Review - 2015', provides an overview of the ArQule, Inc.'s pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of ArQule, Inc.'s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides brief overview of ArQule, Inc. including business description, key information and facts, and its locations and subsidiaries
  • The report reviews current pipeline of ArQule, Inc.'s human therapeutic division and enlists all their major and minor projects
  • The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones
  • Special feature on out-licensed and partnered product portfolio
  • The report summarizes all the dormant and discontinued pipeline projects
  • Latest company statement
  • Latest news and deals relating to the ArQule, Inc.'s pipeline products

Reasons to buy

  • Evaluate ArQule, Inc.'s strategic position with total access to detailed information on its product pipeline
  • Assess the growth potential of ArQule, Inc. in its therapy areas of focus
  • Identify new drug targets and therapeutic classes in the ArQule, Inc.'s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
  • Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
  • Develop strategic initiatives by understanding the focus areas of ArQule, Inc. and exploit collaboration and partnership opportunities
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Plan mergers and acquisitions effectively by identifying the most promising pipeline of ArQule, Inc.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Explore the dormant and discontinued projects of ArQule, Inc. and identify potential opportunities in those areas
  • Avoid Intellectual Property Rights related issues

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • ArQule, Inc. Snapshot
    • ArQule, Inc. Overview
    • Key Information
    • Key Facts
  • ArQule, Inc. - Research and Development Overview
    • Key Therapeutic Areas
  • ArQule, Inc. - Pipeline Review
    • Pipeline Products by Stage of Development
    • Pipeline Products - Monotherapy
  • ArQule, Inc. - Pipeline Products Glance
    • ArQule, Inc. - Late Stage Pipeline Products
      • Phase III Products/Combination Treatment Modalities
    • ArQule, Inc. - Clinical Stage Pipeline Products
      • Phase II Products/Combination Treatment Modalities
      • Phase I Products/Combination Treatment Modalities
    • ArQule, Inc. - Early Stage Pipeline Products
      • Preclinical Products/Combination Treatment Modalities
      • Discovery Products/Combination Treatment Modalities
  • ArQule, Inc. - Drug Profiles
    • tivantinib
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • ARQ-087
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • ARQ-092
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • ARQ-761
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • ARQ-751
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Small Molecules to Inhibit BTK for Cancer
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Small Molecules to Inhibit S6K for Cancer
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Small Molecules to Inhibit Kinase for Oncology
      • Product Description
      • Mechanism of Action
      • R&D Progress
  • ArQule, Inc. - Pipeline Analysis
    • ArQule, Inc. - Pipeline Products by Target
    • ArQule, Inc. - Pipeline Products by Route of Administration
    • ArQule, Inc. - Pipeline Products by Molecule Type
    • ArQule, Inc. - Pipeline Products by Mechanism of Action
  • ArQule, Inc. - Recent Pipeline Updates
  • ArQule, Inc. - Dormant Projects
  • ArQule, Inc. - Discontinued Pipeline Products
    • Discontinued Pipeline Product Profiles
      • ARQ-171
      • tivantinib
  • ArQule, Inc. - Company Statement
  • ArQule, Inc. - Locations And Subsidiaries
    • Head Office
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • ArQule, Inc., Key Information
  • ArQule, Inc., Key Facts
  • ArQule, Inc. - Pipeline by Indication, 2015
  • ArQule, Inc. - Pipeline by Stage of Development, 2015
  • ArQule, Inc. - Monotherapy Products in Pipeline, 2015
  • ArQule, Inc. - Phase III, 2015
  • ArQule, Inc. - Phase II, 2015
  • ArQule, Inc. - Phase I, 2015
  • ArQule, Inc. - Preclinical, 2015
  • ArQule, Inc. - Discovery, 2015
  • ArQule, Inc. - Pipeline by Target, 2015
  • ArQule, Inc. - Pipeline by Route of Administration, 2015
  • ArQule, Inc. - Pipeline by Molecule Type, 2015
  • ArQule, Inc. - Pipeline Products by Mechanism of Action, 2015
  • ArQule, Inc. - Recent Pipeline Updates, 2015
  • ArQule, Inc. - Dormant Developmental Projects,2015
  • ArQule, Inc. - Discontinued Pipeline Products, 2015

List of Figures

  • ArQule, Inc. - Pipeline by Top 10 Indication, 2015
  • ArQule, Inc. - Pipeline by Stage of Development, 2015
  • ArQule, Inc. - Monotherapy Products in Pipeline, 2015
  • ArQule, Inc. - Pipeline by Top 10 Target, 2015
  • ArQule, Inc. - Pipeline by Top 10 Route of Administration, 2015
  • ArQule, Inc. - Pipeline by Top 10 Molecule Type, 2015
  • ArQule, Inc. - Pipeline Products by Top 10 Mechanism of Action, 2015
Back to Top